- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Michael Thompson on Employers Taking a Much Harder Look at Their PBMs | 2023 PBMI Annual National Conference
Thompson, the president and CEO of the National Alliance of Healthcare Purchaser Coalitions, said rebates and pass through are just the “tip of the iceberg” of the misalignment between employers and PBMs that disadvantages employers.
In a brief interview after speaking at the 2023 PBMI conference, Thompson also discussed the fiduciary responsibilities of employers and the conflicts of interest that many consultants who advise employers about their PBM contracts have.
“What is increasingly concerning … the advisers themselves are not working for the employers, they are actually working for the PBMs, because they are actually getting paid more by the PBM than they are getting paid by the employers. And it is a huge part of their business model and creates conflicts that probably creep into why they do things the way they do them. If you are looking for someone to take an independent look they got to be independent,” Thompson said.
Michael Thompson on Employer-PBM Relations and What It Will Take to Change Them
September 12th 2023Thompson, the president of the National Alliance of Healthcare Purchaser Coalitions, said if that 20% of the market changes way it deals with PBMs “it will change the market, it will change the conversation, it will change the practices of key players.”
Read More
Patient, Provider Support is Key for Biosimilar Adoption| 2023 PBM I Annual National Conference
September 8th 2023There is a huge opportunity for savings from the recently launched Humira biosimilars and others expected to reach the market in the next few years. But plans and PBMs will need to step into the role that pharmaceutical manufacturers once did in supporting patients and prescribers.
Read More
Strategies for Paying for Gene and Cell Therapies | 2023 PBMI Annual National Conference
September 7th 2023As cell- and gene-based therapies become available for new and expanded indications with a higher incidence of patients, payers will be challenged to find ways to provide access to patients.
Read More
